NuGen has launched Ovation Fusion Panel Target Enrichment System, an assay that will detect all possible fusion events involving 446 cancer fusion genes. The assay uses NuGen's proprietary Single Primer Enrichment Technology, a single primer strategy that requires only one partner exon to be targeted, which enables detection of both known and novel fusion events, as well as alternative isoforms, according to the company. It requires 10 ng of total RNA from either fresh frozen or formalin-fixed paraffin-embedded tissue.
New Products: NuGen's Ovation Fusion Panel
Aug 27, 2014